Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery

• Pacira BioSciences Inc (NASDAQ: PCRX) announced topline results from its Phase 3 study of EXPAREL as a single-dose sciatic nerve block in the popliteal fossa for postsurgical regional analgesia in patients undergoing bunionectomy, correcting the deformity of the bones making up the toe and foot.

• EXPAREL achieved the study's primary endpoint by demonstrating a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine HCl.

• Related Content: Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug.

• EXPAREL also achieved statistical significance for the reduction in postsurgical opioid consumption and percentage of opioid-free subjects through 96 hours compared with bupivacaine HCl.

• EXPAREL was well tolerated with a safety profile consistent with bupivacaine HCl.

• Pacira plans to submit a supplemental marketing application to the FDA early next year to expand the EXPAREL label to include sciatic nerve blocks in the popliteal fossa, as well as femoral nerve blocks in the adductor canal.

• Price Action: PCRX shares are up 3.03% at $56.70 on the last check Wednesday.

See more from Benzinga

• Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug

• Trump's Not Going To Like These New Poll Numbers: Why His Numbers Are Sliding

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.